Phase 3 N=204 Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Blunt Trauma Injuries
Acute Blunt Soft Tissue Injuries/Contusions
Primary: Pain on Movement — 33.1; 65.4 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=795 A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6 — 52.73; 58.25; 31.21 percentage of participants — p=<0.0001
Phase 3 N=717 A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6 — 51.53; 52.55; 28.30; 47.24 percentage of participants — p=<0.0001
Phase 3 N=264 Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis
Tinea Pedis · Athlete's Foot
Primary: Complete Cure — 63; 81; 19; 2 Participants
Phase 3 N=800 A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6 — 51.46; 61.81; 25.32 percentage of participants — p=<0.0001
Phase 3 N=72 A Randomized, Self Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing
Tooth Extractions
Primary: Time to Hemostasis — 1.9; 9.8; 6.0 Minutes
Phase 3 N=324 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico
Pneumococcal Infections
Primary: Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination — 120; 84; 88; 89 titer
Phase 3 N=115 Study of Antidepressants in Parkinson's Disease
Parkinson Disease · Depression
Primary: Change in Hamilton Depression Rating Scale (HAM-D) Scores — -13.0; -11.0; -6.8 Change in HAM-D score
Phase 3 N=251 Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients
Chronic Obstructive Pulmonary Disease
Primary: Clinical Laboratory Test: Haematology -Erythrocytes — -6.25; -5.2 erythrocytes counts x10000/μl
Phase 3 N=913 A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Carcinoma · Non Small Cell Lung
Primary: Overall Survival (OS) — 10.41; 10.05 months — p=0.8985
Phase 3 N=30 Comparison of Two Urostomy Bags (2-piece).
Urostomy Patent
Primary: Preference of the Two Urostomy Products — 21; 4 participants
Phase 3 N=55 Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Ovarian Neoplasms · Ascites
Primary: Time to Repeat Paracentesis (TRP) — 23.3; 55.1 days — p=0.0019
Phase 3 N=151 Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Pulmonary Hypertension
Primary: Change From Baseline to All Assessed Time Points in 6-minute Walk Test (6MWT) Distance — 8.4; 18.2; 17.7; 20.2 walk distance change from baseline (m)
Phase 3 N=691 A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 26. — -1.43; -1.12 percentage of total hemoglobin — p=<.001
Phase 3 N=349 Metoclopramide for Migraine: A Dose Finding Study
Migraine
Primary: Pain Intensity Score — 4.7; 4.9; 5.3 scores on a scale